Trial site
Ziv Medical Center
Safed, 13100, IsraelNot linked to an institution yet
- 13running trials
- 14closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 24 trials
- Phase 2/33 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Completed14 trials
- Active, not recruiting7 trials
- Recruiting4 trials
- Enrolling by invitation2 trials
- Lead sponsor
- Cytokinetics4 trials
- Janssen Research & Development, LLC4 trials
- Agios Pharmaceuticals, Inc.2 trials
- Eli Lilly and Company2 trials
- AbbVie1 trial
- and 14 more
Running trials
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Contact: Majdi Halabi (principal investigator)
Recruiting
The Role of FAPI PET-CT in Diagnosing Endometriosis
NCT06792318· Ziv Hospital· Source
Contact: Israel Sandler, MD
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· CSL Behring· Source
Contact: Trial Registration Coordinator
Active, not recruiting
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· Phase 3· Cytokinetics· Source
Enrolling by invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993· Phase 4· Agios Pharmaceuticals, Inc.· Source
Recruiting
POST URS Chemotherapy Instillation
NCT06167057· Carmel Medical Center· Source
Contact: Ran Katz, Dr
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555· Phase 1/2· Incyte Corporation· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source
Enrolling by invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506· Phase 2/3· Cytokinetics· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06490445· Phase 2· Syqe Medical· Source
Completed
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480· Phase 2· Shionogi· Source
Completed
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346· Phase 3· Cytokinetics· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
NCT05514548· Phase 2· Inversago Pharma Inc.· Source
Completed
Evaluation in STEMI Patients Using FDY-5301
NCT04837001· Phase 3· Faraday Pharmaceuticals, Inc.· Source
Completed
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05186818· Phase 3· Cytokinetics· Source
Completed
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
NCT04509674· Phase 3· Boehringer Ingelheim· Source
Completed
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
NCT04612413· Phase 2· Enlivex Therapeutics Ltd.· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· Phase 3· AbbVie· Source
Completed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· Phase 3· Daiichi Sankyo· Source
Completed
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954· Phase 3· Takeda· Source
Completed
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
NCT03232073· Phase 3· Actelion· Source
Report an error